fda glp-1 compounding enforcement news october 2025 Ozempic's patent problem: how Novo Nordisk lost control of a blockbuster drug. 💉 Demand for weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite FDA and Novo Nordisk Warn

In PsO, clinical studies evaluating GLP-1RAs such as liraglutide and semaglutide have reported significant improvements in PASI scores and histopathological skin features, effects that appear to be at least partially independent of weight loss ( Given the prominent role of IL-17driven inflammation in obese PsA patients, GLP-1RAs may also enhance the efficacy of biologic agents targeting these pathways

Its well known that having a homozygous mutation is more likely to cause health problems and having a heterozygous mutation is unlikely to cause issues

Mounjaro and Bipolar Disorder: Safety, Interactions and Guidance Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist licensed in the UK for type 2 diabetes and weight management

PlexusDx's month-to-month rates run roughly $60$70/mo below Fridays' advertised month-to-month for both compounds, though Fridays' prepaid 3- and 6-month bundles undercut PlexusDx per month and Fridays includes coaching and dietitian support